168 related articles for article (PubMed ID: 37980651)
21. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
22. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
23. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
[TBL] [Abstract][Full Text] [Related]
25. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
26. DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.
Lu Y; Chang P; Bian J; Zhu L
Cancer Biomark; 2023; 38(3):393-407. PubMed ID: 37955080
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.
Fang Z; Lin L; Tu Z; Zhu X; Li J; Luo P; Huang K; Wu L
Cancer Med; 2023 Jan; 12(1):712-732. PubMed ID: 35702880
[TBL] [Abstract][Full Text] [Related]
28. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
29. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
[TBL] [Abstract][Full Text] [Related]
31. Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.
Shi B; Ge F; Cai L; Yang Y; Guo X; Wu R; Fan Z; Cao B; Wang N; Si Y; Lin X; Dong W; Sun H
Front Immunol; 2023; 14():1247288. PubMed ID: 38022677
[TBL] [Abstract][Full Text] [Related]
32. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
33. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-32 targeting PTEN enhances M2 macrophage polarization in the glioma microenvironment and further promotes the progression of glioma.
Bao L; Li X
Mol Cell Biochem; 2019 Oct; 460(1-2):67-79. PubMed ID: 31218569
[TBL] [Abstract][Full Text] [Related]
36. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
[TBL] [Abstract][Full Text] [Related]
37. A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma.
Zhang Y; Yang X; Zhu XL; Wang ZZ; Bai H; Zhang JJ; Hao CY; Duan HB
Front Oncol; 2021; 11():643159. PubMed ID: 33937046
[TBL] [Abstract][Full Text] [Related]
38. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
39. Predictive significance of PRR11 in prognosis and immune infiltration of glioma patients.
Han W; Chen L
Mol Carcinog; 2023 Jul; 62(7):975-990. PubMed ID: 37036189
[TBL] [Abstract][Full Text] [Related]
40. Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.
Zhao Z; Zhao J; Wang Z; Wu Y; Zhang Z; Song Z; Miao J; Liu B; Zhang S; Sun B; Zhao Z
Int J Immunopathol Pharmacol; 2022; 36():3946320221104548. PubMed ID: 35609253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
